Summary
Vertex Pharmaceuticals Inc. reported a net loss attributable to Vertex of $57.5 million for the third quarter of 2012, a significant change from the $221.1 million net income reported in the same period of the prior year. This shift was primarily driven by a substantial decrease in collaborative revenues, largely due to the absence of milestone payments received in the prior year, and a decline in INCIVEK product revenues. Total revenues for the quarter fell to $336.0 million from $659.2 million year-over-year. Despite the revenue decrease, operating costs and expenses were reduced, largely due to the absence of a significant intangible asset impairment charge recorded in the prior year. For the nine-month period ended September 30, 2012, Vertex reported a net loss attributable to Vertex of $30.9 million, an improvement compared to a net loss of $129.1 million in the same period of 2011. This improvement was driven by a significant increase in product revenues, more than doubling to $1.05 billion, primarily from the launch of KALYDECO and continued sales of INCIVEK, alongside increased royalty revenues. However, collaborative revenues decreased substantially. The company ended the period with $1.3 billion in cash, cash equivalents, and marketable securities, providing a strong liquidity position to fund ongoing research and development and commercialization efforts.
Financial Highlights
49 data points| Revenue | $336.01M |
| Cost of Revenue | $30.68M |
| Gross Profit | $305.33M |
| R&D Expenses | $200.16M |
| SG&A Expenses | $97.68M |
| Operating Expenses | $337.08M |
| Operating Income | -$1.07M |
| Interest Expense | -$13K |
| Net Income | -$57.54M |
| EPS (Basic) | $-0.27 |
| EPS (Diluted) | $-0.27 |
| Shares Outstanding (Basic) | 213.77M |
| Shares Outstanding (Diluted) | 213.77M |
Key Highlights
- 1Total revenues decreased by 49% to $336.0 million in Q3 2012 compared to $659.2 million in Q3 2011, primarily due to a significant drop in collaborative revenues.
- 2Net loss attributable to Vertex was $57.5 million ($0.27 per diluted share) in Q3 2012, compared to a net income of $221.1 million ($1.02 per diluted share) in Q3 2011.
- 3Product revenues increased by 113% to $1.05 billion for the nine months ended September 30, 2012, driven by INCIVEK and the newly launched KALYDECO.
- 4The company recorded a $78.0 million charge for excess and obsolete INCIVEK inventories in the second quarter of 2012.
- 5Research and development expenses increased by 6% to $200.2 million in Q3 2012 compared to $189.1 million in Q3 2011, indicating continued investment in pipeline development.
- 6Vertex maintained a strong liquidity position with $1.3 billion in cash, cash equivalents, and marketable securities as of September 30, 2012.